Clareo Health | A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The trial was terminated on 12 April, 2012 due to lack of efficacy at the Week 24 analysis. The decision to terminate the trial was not based on any safety concerns.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.
HIV 1 RNA viral load of greater then 500 copies/mL.
Negative urine pregnancy test.
You may not be if
Suspected or documented active, untreated HIV-1 related opportunistic infection or other condition requiring acute therapy at the time of randomization.
Subjects with acute Hepatitis B and/or C within 30 days of randomization.
